Deutsch
Englisch
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)
PATIENTS
Recruitment was stopped on the 27th of May 2022.
1240 patients enrolled (136 in Germany)
55 sites open (10 in Germany)
Status as of 06th of May 2022
1.572
(375 in Germany)
Planned number of participants
PARTICIPATING COUNTRIES
Australia, Belgium, China, Germany, Israel, Italy, Canada
Chief International Investigators
Dr. David H. Birnie, Ottawa Heart Institute Research Corporation, Canada
Dr. Atul Verma, Southlake Regional Health Center, Ontario, Canada
Dr. Gerhard Hindricks, Leipzig Heart Centre, Germany
Overall Responsibility
Sponsor:
Ottawa Heart Institute Research Corporation (OHIRC), Canada
Legal Sponsor Representative for Europe:
Atrial Fibrillation NETwork (AFNET), Münster, Germany